This morning Sarepta released the 168 week data on eteplirsen.  

For weeks there has been speculation, guesses, and hope about what we might learn.  We have been following the stories on social media, grateful for every photo or video. We are thrilled that the open label eteplirsen studies (confirmatory study and non ambulatory study) are actively recruiting and are anxiously awaiting the timeline for follow-on exons.

For years we have suggested the benefit/risk equation is different in Duchenne than in other diseases and PPMD's benefit/risk pilot confirmed and quantified the equation. Parents highest priority – second  only to a cure – is  to slow disease progression.

The 168 week data exceeds our expectations. Eteplirsen slows the rate of progression, delays the loss of ambulation, and preserves respiratory function.

We must keep in mind that the brave young men in the study, all 12 of them, were 9+/- years of age when starting the study.   When entering the study, their muscles had already been damaged  because dystrophin was absent, resulting in an unhealthy cellular environment.  The dystrophin that was confirmed after 48 weeks has led to this long-term benefit through 168 weeks. After 168 weeks, their rate of decline was far less than predicted.

Slowing degeneration, preserving ambulation, stabilizing respiratory function preserve the quality of life for these young men, helping to maintain the integrity of the spine and delay the need for non invasive ventilation.

We all recognize that it will take a combination of drugs to stop progression, that doctors will need an arsenal of tools to deliver precision medicines for every individual diagnosed. Eteplirsen meets the criteria as an effective drug to slow progression.

As a community we fully support eteplirsen as a therapy. We completely understand that treating people with Duchenne earlier will likely provide additional benefits. We also agree that slowing progression for all individuals, no matter the age or stage, is critically important and we support all efforts to fully exploit this technology.

We are and continue to be believers.

Views: 1921


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Comment by Shelly on January 22, 2015 at 1:22am
We do believe!
Comment by Barbara Del Rio on January 16, 2015 at 12:17pm

When will they work on therapies for men with deletions 22 - 26. I just don't know what to think about this because my son is in his 20's and it feels like we are running out of time. Why do I not hear of research for DMD in this category?

Comment by Tracy Seckler on January 12, 2015 at 10:09am

Right on!

Need help using this community site? Visit Ning's Help Page.



© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service